KCM
DCPH

Kingdon Capital Management’s Deciphera Pharmaceuticals, Inc. Common Stock DCPH Stock Holding History

Kingdon Capital Management’s Portfolio DCPH Stock Details DCPH Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q3 		– Sell
-100,000
Closed -$2.25M – 84
2019
Q2 		$2.25M Buy
+100,000
New +$2.34M 0.22% 60

Other funds holding DCPH

AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return
NLVP
New Leaf Venture Partners New York $43M AUM 25.55% 1-Year Est. Return
Canada Pension Plan Investment Board
Canada Pension Plan Investment Board Toronto Ontario, Ontario, Canada $155B AUM 29.93% 1-Year Est. Return
JG
Jefferies Group New York $12B AUM 6.2% 1-Year Est. Return
Assenagon Asset Management
Assenagon Asset Management Senningerberg, Luxembourg $80.2B AUM 50.57% 1-Year Est. Return

Kingdon Capital Management's DCPH Position: Q3 2019 in Review

Kingdon Capital Management sold out of Deciphera Pharmaceuticals, Inc. Common Stock (DCPH) in Q3 2019, closing a stake of 296,346 shares — an estimated $6.68M sold.

Kingdon Capital Management first reported a position in DCPH in Q1 2019 and held it in 2 quarters. The position peaked at $6.68M in Q2 2019. 122 funds tracked by Wall St. Rank hold DCPH as of Q3 2019.

  • Kingdon Capital Management reported no remaining Deciphera Pharmaceuticals, Inc. Common Stock position as of Q3 2019 after selling out during the quarter.
  • Kingdon Capital Management sold 296,346 Deciphera Pharmaceuticals, Inc. Common Stock shares in Q3 2019, an estimated $6.68M.
  • Kingdon Capital Management first reported a position in Deciphera Pharmaceuticals, Inc. Common Stock in Q1 2019 and held it in 2 quarters.
  • Kingdon Capital Management's Deciphera Pharmaceuticals, Inc. Common Stock position peaked at $6.68M in Q2 2019.
  • 122 funds tracked by Wall St. Rank held Deciphera Pharmaceuticals, Inc. Common Stock as of Q3 2019.

Based on Kingdon Capital Management's 13F filing for Q3 2019, filed 14 Nov 2019.